Venture Map · Round
Highlight Therapeutics — Series B · €15M
Announced 2025-09-16 · Valencia · Biotech / Immuno-oncology
Valencia-based Highlight Therapeutics closed a €15M round led by Buenavista Equity Partners through its BV Healthcare Growth Innvierte I fund, created with Columbus Venture Partners. The money funds the Phase 2b trial of BO-112, an intratumoral immunotherapy for basal cell carcinoma originally discovered at Spain's CNIO in 2009.
RoundSeries B
Amount€15M
LeadBuenavista Equity Partners
Date2025-09-16
CityValencia
SectorBiotech / Immuno-oncology
